Form 8-K - Current report:
SEC Accession No. 0001193125-22-299475
Filing Date
2022-12-06
Accepted
2022-12-06 17:04:32
Documents
12
Period of Report
2022-11-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d423428d8k.htm   iXBRL 8-K 27738
  Complete submission text file 0001193125-22-299475.txt   145574

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bbio-20221130.xsd EX-101.SCH 2844
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20221130_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20221130_pre.xml EX-101.PRE 10808
6 EXTRACTED XBRL INSTANCE DOCUMENT d423428d8k_htm.xml XML 3199
Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 221448372
SIC: 2834 Pharmaceutical Preparations